Contineum Therapeutics
NASDAQ: CTNM3 known investors
Contineum Therapeutics develops therapies targeting conditions at the intersection of inflammatory and fibrotic diseases, including a candidate for idiopathic pulmonary fibrosis (IPF) and chronic pain, and a candidate for major depressive disorder (MDD) developed with Janssen Pharmaceutica. It is a clinical-stage biopharmaceutical company focused on patients with limited treatment options.
BiotechHealthtech
Investors · 3
Competitors · 2
by search overlapBioworld30 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
Clinicaltrialsarena19 shared keywordsClinical Trials Arena is an online news and information publication covering the clinical trials industry, including trends, regulatory developments, and industry events. It serves professionals working in pharmaceutical and clinical research.
Companies competing with Contineum Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.
Frequently asked questions
- What does Contineum Therapeutics do?
- Contineum Therapeutics develops therapies targeting conditions at the intersection of inflammatory and fibrotic diseases, including a candidate for idiopathic pulmonary fibrosis (IPF) and chronic pain, and a candidate for major depressive disorder (MDD) developed with Janssen Pharmaceutica. It is a clinical-stage biopharmaceutical company focused on patients with limited treatment options.
- Who are Contineum Therapeutics's investors?
- Contineum Therapeutics's investors include Hadean Ventures, Red Tree Venture, Samsara BioCapital.